China Biologic Products (CBPO -6.5%) takes a hit today after receiving notification from the Guizhou Provincial Health Department that the government has suspended the company's blood collection activities in the province. The suspension affects four of six collection sites it runs, and the impact upon current business operations could be significant.
From other sites
at Zacks.com (Feb 25, 2015)
at Investor's Business Daily (Jan 8, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs